Axsome Therapeutics (Axsome Therapeutics) Days Sales Outstanding

: 110.50 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Axsome Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $86.6 Mil. Axsome Therapeutics's Revenue for the three months ended in Dec. 2023 was $71.5 Mil. Hence, Axsome Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 110.50.

The historical rank and industry rank for Axsome Therapeutics's Days Sales Outstanding or its related term are showing as below:

AXSM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 87.17 Med: 182.19 Max: 275
Current: 87.17

During the past 11 years, Axsome Therapeutics's highest Days Sales Outstanding was 275.00. The lowest was 87.17. And the median was 182.19.

AXSM's Days Sales Outstanding is ranked worse than
59.01% of 888 companies
in the Biotechnology industry
Industry Median: 72.335 vs AXSM: 87.17

Axsome Therapeutics's Days Sales Outstanding increased from Dec. 2022 (108.58) to Dec. 2023 (110.50).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Axsome Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Axsome Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

275.00

89.37

Axsome Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															108.58	39.80	109.62	115.12	110.50

Competitive Comparison

For the Biotechnology subindustry, Axsome Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Days Sales Outstanding falls into.

Axsome Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Axsome Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (37.699	+	94.82)	/	2 )	/	270.6	*	365
=	66.2595					/	270.6	*	365
=	89.37

Axsome Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (78.415	+	94.82)	/	2 )	/	71.53	*	365 / 4
=	86.6175					/	71.53	*	365 / 4
=	110.50

Axsome Therapeutics (NAS:AXSM) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Axsome Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics (Axsome Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

19X:Germany 19X:Germany

Address

22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Executives

Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman	director	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock	officer: General Counsel	22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs	director
Nick Pizzie	officer: Chief Financial Officer	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad	director	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson	officer: Chief Operating Officer	200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek	officer: Chief Commercial Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski	officer: Chief Financial Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye	officer: Chief Medical Officer	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance	officer: Vice President, Finance	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc	10 percent owner	630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111